Literature DB >> 1384222

Tenascin in salivary gland tumours.

Y Soini1, P Pääkkö, I Virtanen, V P Lehto.   

Abstract

The distribution of tenascin immunoreactivity was analysed in salivary gland tissue and in various benign and malignant tumours of the salivary gland. In the non-neoplastic tissue, tenascin was seen in the areas of basement membranes of the ductal epithelium. No immunoreactivity could be observed in the serous or mucous glands. In pleomorphic adenomas, tenascin immunoreactivity could be seen in the stromal compartment. It was more pronounced in the dense stromal areas and chondroid elements than in the myxoid area. In Warthin's tumours, strong tenascin immunoreactivity could be observed in the basement membrane zone of the epithelial component. In the lymphatic component, faint reticular staining could be seen. In adenoid cystic carcinomas, acinic cell tumours and mucoepidermoid carcinomas, tenascin showed a linear stromal distribution. No intracytoplasmic immunoreactivity could be seen in any of the cases. The widespread tenascin positivity in salivary gland tumours suggests that tenascin may play a role in the induction and progression of salivary gland tumours, presumably by interfering with the normal parenchymal-mesenchymal interaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384222     DOI: 10.1007/bf01611178

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  25 in total

Review 1.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.

Authors:  H P Erickson; M A Bourdon
Journal:  Annu Rev Cell Biol       Date:  1989

2.  Tenascin expression in the human endometrium and in endometrial adenocarcinomas.

Authors:  G Vollmer; G P Siegal; R Chiquet-Ehrismann; V A Lightner; H Arnholdt; R Knuppen
Journal:  Lab Invest       Date:  1990-06       Impact factor: 5.662

3.  Expression and production of tenascin in benign and malignant lesions of melanocyte lineage.

Authors:  P G Natali; M R Nicotra; A Bartolazzi; M Mottolese; N Coscia; A Bigotti; L Zardi
Journal:  Int J Cancer       Date:  1990-10-15       Impact factor: 7.396

4.  Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast.

Authors:  A A Howeedy; I Virtanen; L Laitinen; N S Gould; G K Koukoulis; V E Gould
Journal:  Lab Invest       Date:  1990-12       Impact factor: 5.662

5.  Epithelial synthesis of tenascin at tips of growing bronchi and graded accumulation in basement membrane and mesenchyme.

Authors:  M Koch; B Wehrle-Haller; S Baumgartner; J Spring; D Brubacher; M Chiquet
Journal:  Exp Cell Res       Date:  1991-06       Impact factor: 3.905

6.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

Authors:  M A Bourdon; C J Wikstrand; H Furthmayr; T J Matthews; D D Bigner
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

7.  Tenascin: cDNA cloning and induction by TGF-beta.

Authors:  C A Pearson; D Pearson; S Shibahara; J Hofsteenge; R Chiquet-Ehrismann
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

8.  Tenascin mediates cell attachment through an RGD-dependent receptor.

Authors:  M A Bourdon; E Ruoslahti
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

9.  Site-restricted expression of cytotactin during development of the chicken embryo.

Authors:  K L Crossin; S Hoffman; M Grumet; J P Thiery; G M Edelman
Journal:  J Cell Biol       Date:  1986-05       Impact factor: 10.539

10.  Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis.

Authors:  M Chiquet; D M Fambrough
Journal:  J Cell Biol       Date:  1984-06       Impact factor: 10.539

View more
  4 in total

1.  Clinical and immunohistochemical analyses of parotid gland tumors.

Authors:  W Ozdziński; J Kuczkowski; E Debniak; A Zołtowska
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

2.  Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation.

Authors:  A Juuti; S Nordling; J Louhimo; J Lundin; C Haglund
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

3.  Tenascin immunoreactivity in normal and pathological bone marrow.

Authors:  Y Soini; D Kamel; M Apaja-Sarkkinen; I Virtanen; V P Lehto
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

4.  Tenascin and fibronectin in pleomorphic adenoma of the salivary gland.

Authors:  Patrícia Meira Bento; Roseana de Almeida Freitas; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  J Appl Oral Sci       Date:  2006-06       Impact factor: 2.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.